# KLOW Peptide: Four Currents of Repair, Read Study by Study

> KLOW peptide is a research-only four-component blend — KPV, GHK-Cu, BPC-157 and TB-500 — each studied independently. Skin matrix, anti-inflammation, angiogenesis, cell migration: one vial, four separate research records.

KPV quenches the cytokine fire. GHK-Cu reweaves the matrix. BPC-157 opens new vessels. TB-500 moves the cells. Four arms of one cascade — studied separately, combined in one vial, never tested as a whole.

## The short version

KLOW peptide is a research blend of four separate compounds — KPV, GHK-Cu, BPC-157 and TB-500 — co-dissolved in one vial, most commonly at 80 mg total (GHK-Cu 50 mg + BPC-157 10 mg + TB-500 10 mg + KPV 10 mg). Each ingredient has its own published research story. GHK-Cu (the copper-carrying tripeptide) is the dominant component and is studied for collagen synthesis and broad gene-expression changes in skin. KPV is a tiny anti-inflammatory tripeptide derived from a natural hormone, studied for quieting gut and tissue inflammation. BPC-157 is a synthetic peptide from gastric juice, studied for tendon and gut repair through new blood-vessel growth. TB-500 is a fragment of a protein called thymosin beta-4, studied for helping cells move into and seal a wound. None of the four is FDA-approved. The blend itself has never been tested in a controlled study — every benefit claim comes from single-compound research, not a blend trial. What people report — including the downsides — is on the [KLOW effects](/effects) page.

## What is KLOW peptide

KLOW peptide is a co-formulated research blend of four chemically distinct peptides supplied in a single lyophilized vial. They do not fuse into one molecule — they remain separate substances dissolved together at fixed ratios. The canonical composition across independent research compounders is: GHK-Cu (glycyl-l-histidyl-l-lysine copper complex) 50 mg, BPC-157 (body protection compound 157) 10 mg, TB-500 (Ac-LKKTETQ, the actin-binding fragment of thymosin beta-4) 10 mg, and KPV (lysine-proline-valine, the C-terminal tripeptide of alpha-melanocyte-stimulating hormone, or alpha-MSH) 10 mg — 80 mg total.

The architecture is deliberate. GHK-Cu at ~62.5% by mass (50 of 80 mg) anchors the blend as the matrix and skin-remodeling arm, with decades of topical and in-vitro research behind it. The other three components occupy non-overlapping nodes of one tissue-repair signaling network: KPV suppresses the cytokine and NF-kB (a transcription factor that drives inflammatory gene expression) cascade, BPC-157 drives the VEGFR2/PI3K/Akt/eNOS angiogenic axis (the pathway cells use to build new blood vessels), and TB-500's LKKTET fragment sequesters G-actin (monomeric, globular actin — the raw material cells use to build a new leading edge and migrate).

Crucially, no controlled in-vivo or human study has tested the four-peptide KLOW blend itself — against monotherapy, against any subset, or against placebo. The combination rationale is mechanistic extrapolation from the single-component literature, and a pharmacokinetic mismatch (the tripeptides KPV and GHK-Cu clear far faster than BPC-157) is inherent in a co-formulated vial.

## KLOW blend

The KLOW peptide blend is not a new chemical entity. It is four separate molecules sharing one vial — a co-formulation, not a fusion. Its four arms address largely non-overlapping steps of the same tissue-repair cascade: cytokine suppression (KPV), extracellular-matrix synthesis (GHK-Cu), new-vessel growth (BPC-157), and cell migration / re-epithelialization (TB-500/thymosin beta-4). The mechanistic logic is that these steps are complementary and partly sequential — inflammation is quieted, matrix is rebuilt, a blood supply is routed in, and cells are moved into position. But the word 'synergy' carries more weight than the evidence can hold: no blend-level experiment has confirmed that the four components interact in the way the mechanism sketch suggests [1].

The [klow stack](/blend-components) page walks each constituent's published research in depth — the dose-range data, the species, the route, and the honest gaps in each arm's evidence.

## KLOW peptide benefits

The benefits attributed to KLOW peptide come from the component literature, not from any study of the blend. Each arm has its own published signal:

GHK-Cu (the skin-matrix arm) stimulated collagen synthesis in human fibroblast cultures in a dose-dependent manner — stimulation beginning between 10⁻¹² and 10⁻¹¹ M and maxing at 10⁻⁹ M, with no change in cell number [8]. In a 6-month trial in 45 men with androgenetic alopecia, a topical GHK-containing complex increased hair count by 52.6 (100 mg/mL dose) and 71.5 (50 mg/mL dose) versus 9.6 for placebo (p<0.05), with no adverse events [11]. A broader review documents GHK-Cu stimulating collagen, dermatan sulfate, chondroitin sulfate and the proteoglycan decorin, while plasma GHK declines from about 200 ng/mL at age 20 to about 80 ng/mL by age 60 [4].

KPV (the anti-inflammatory arm) inhibited NF-kB and MAP-kinase inflammatory signaling and reduced TNF-alpha, IL-6 and IL-1beta secretion at nanomolar concentrations in human intestinal and immune cells, and oral KPV reduced the severity of DSS- and TNBS-induced colitis in mice [3].

BPC-157 (the angiogenic arm) accelerated healing of a fully transected rat Achilles tendon across biomechanical, functional, microscopic and macroscopic measures and stimulated tendocyte outgrowth in vitro [2]. A 2025 safety pilot documented intravenous BPC-157 up to 20 mg in two healthy adults was well tolerated with no observed adverse events and no measurable biomarker changes [6].

TB-500/thymosin beta-4 (the cell-migration arm): in a rat full-thickness wound model, topical or IP thymosin beta-4 increased re-epithelialization by 42% at 4 days and up to 61% at 7 days versus saline, increased wound contraction (≥11% by day 7) and raised collagen deposition and angiogenesis; as little as 10 pg stimulated keratinocyte migration 2-3-fold [1].

Every figure above belongs to one constituent, studied alone, in specific species and routes. Attribution is structural — the benefit of a single-component finding cannot be carried forward as evidence for the blend.

## KLOW vs glow

KLOW and GLOW are related but distinct blends. GLOW is a three-peptide blend of GHK-Cu, BPC-157 and TB-500. KLOW adds KPV — the anti-inflammatory tripeptide derived from alpha-MSH — as a fourth component, typically at 10 mg in the canonical 80 mg vial. That addition has a specific mechanistic rationale: KPV targets the NF-kB/MAPK inflammatory axis and is taken up preferentially into inflamed gut and immune cells via the PepT1 (SLC15A1) di/tripeptide transporter [3], a step that the other three components do not directly address.

In the research-use community, KLOW is described as feeling more broadly anti-inflammatory than GLOW, with the gut-comfort signal attributed to the KPV arm. This is community observation, not a head-to-head comparison study. No controlled experiment has compared KLOW to GLOW or to the KPV-free subset in any species.

---

A fog-lit reading room: four component literatures set down as four separate currents, each cited to its own study, the absent blend experiment kept openly dark.